CD38 and Miyoshi myopathy: Indeed, data derived from several clinical studies indicate CD38 as an attractive actionable target for MM, with the expectation that, by simultaneously interfering with several aspects of carcinogenesis, CD38-targeted agents have led to impressive clinical results.